**Table S1.** Summary of the lipids intra-class comparisons in Bevacizumab versus Control samples

**IGROV-1**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Chain lenght** | **Unsaturations** | **Unsaturation Index** |
| **Triacylglycerol** | ↓ \*\* | -- | ↑ \* |
| **Ceramide** | -- | ↑ | ↑ |
| **Glycosyl-Ceramide** | -- | ↑ | ↑ |
| **Sphingomyelin** | ↑ | ↑ \* | ↑ \* |
| **Phosphatidylcholine** | -- | -- | -- |
| **Plasmanyl and Plasmenyl-PC** | ↓ \* | ↓ | ↓ |
| **Phosphatidylethanolamine** | -- | -- | -- |
| **Plasmanyl and Plasmenyl-PE** | ↓ | -- | -- |
| **Diacylglycerol** | ↑ | ↑ | ↑ \* |
| **Lyso-Phosphatidylcholine** | ↓ \*\* | ↑ | ↑ |

**SKOV3**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Chain lenght** | **Unsaturations** | **Unsaturation Index** |
| **Triacylglycerol** | -- | -- | -- |
| **Ceramide** | ↑ \* | ↑ | ↑ |
| **Glycosyl-Ceramide** | -- | ↑ \*\* | ↑ \*\*\* |
| **Sphingomyelin** | ↓ | -- | -- |
| **Phosphatidylcholine** | ↓ \*\* | ↓ \*\* | ↓ \*\* |
| **Plasmanyl and Plasmenyl-PC** | -- | ↑ \* | ↑ \* |
| **Phosphatidylethanolamine** | -- | -- | -- |
| **Plasmanyl and Plasmenyl-PE** | ↓ \*\* | -- | -- |
| **Diacylglycerol** | -- | -- | -- |
| **Lyso-Phosphatidylcholine** | ↓ \* | -- | -- |

Upward and down-ward arrows denote higher and lower values, respectively, in Bevacizumab samples respect to Control. Stars represent the level of significance (\*, p < 0,05; \*\*, p < 0,01; \*\*\*, p < 0,001), whereas missing stars denote non-significant p-values, but still lower than 0,2.